文献速递血管炎

无不良预后因素的嗜酸性肉芽肿性多血管炎:糖皮质激素对比糖皮质激素联合环磷酰胺的目标试验模拟研究

Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该研究利用欧洲多中心回顾性观察数据模拟目标试验,纳入250例新诊断且FFS=0的EGPA患者,比较糖皮质激素单药(177例)与联合环磷酰胺(73例)的12个月总体复发风险。经逆概率治疗加权调整后,联合环磷酰胺未降低总体复发风险,在伴有严重表现但无不良预后因素的患者亚组中结果相似。

要点

  • 在FFS=0的EGPA患者中,糖皮质激素联合环磷酰胺相比单药未降低12个月总体复发风险。
  • 伴有严重表现但无不良预后因素的患者亚组中,联合环磷酰胺同样未显示降低复发风险。
  • 研究结果支持现行指南对无严重表现患者的推荐,但对有严重表现而无不良预后因素者加用环磷酰胺的必要性提出挑战。

核心结论

  • 在无不良预后因素(FFS=0)的EGPA患者中,糖皮质激素联合环磷酰胺相比糖皮质激素单药并未降低总体复发风险。
  • 该结果支持现行指南对无严重表现患者的推荐,但对有严重表现而无不良预后因素者加用环磷酰胺的必要性提出挑战。

研究设计与样本

  • 利用欧洲多中心回顾性观察数据模拟目标试验,纳入新诊断、诊断时FFS=0且接受糖皮质激素或糖皮质激素联合环磷酰胺治疗的EGPA患者。
  • 共纳入250例患者,其中177例接受糖皮质激素单药治疗,73例接受糖皮质激素联合环磷酰胺治疗。
  • 主要结局为12个月总体复发,采用基于逆概率治疗加权的分析调整潜在混杂因素。

主要发现

  • 调整后,糖皮质激素联合环磷酰胺组与糖皮质激素单药组相比,总体复发风险未见降低。
  • 在伴有严重表现但未纳入FFS的患者亚组中,观察到相似结果。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Current recommendations suggest treating eosinophilic granulomatosis with polyangiitis (EGPA) without severe manifestations with glucocorticoids (GCs) and EGPA with severe manifestations with GCs plus cyclophosphamide (CYC) regardless of poor-prognostic factors. However, GCs plus CYC and GCs alone have never been compared in EGPA without poor-prognosis factors assessed by the 1996 Five Factor Score (FFS). We aimed to compare the efficacy of GCs plus CYC vs GCs alone for the treatment of EGPA without poor-prognosis, including among patients with severe manifestations. METHODS: We emulated a target trial using observational data from a European multicentre retrospective study. We included patients with (i) newly diagnosed EGPA, (ii) a FFS = 0 at diagnosis and (iii) treated with GCs or GCs plus CYC. Primary outcome was overall relapse at 12 months. Inverse probability of treatment weighting-based analysis was used to adjust for potential confounding factors. In a subgroup analysis, we focused on patients with severe manifestations not included in the FFS. RESULTS: A total of 250 patients were included: 177 treated with GCs alone and 73 with GCs plus CYC. After adjustment, no reduction in the risk of overall relapse was observed between the two treatment groups. Similar results were observed in the subgroup of patients with severe manifestations. CONCLUSION: This study shows that the adjunction of CYC to GCs does not reduce the risk of relapse in patients with EGPA and no poor-prognosis factors. It supports current guidelines in patients without severe manifestations but challenges the need of CYC adjunction in patients with severe manifestations but no poor-prognosis factors.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sorin B, Papo M, Sinico RA, et al. Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study. Rheumatology (Oxford). 2025. PMID: 40411755. doi:10.1093/rheumatology/keaf256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。